Abstract

Until recently, chemotherapy was the only treatment option for metastatic non-squamous non-small cell lung cancer (NSCLC) without targetable mutations. The introduction of immunotherapies changed the prognosis for patients suffering from this disease. Pembrolizumab can be given as monotherapy or in combination with chemotherapy. So far, it was unclear, if and which of these treatment options is cost-effective for patients with a high programmed death ligand 1 (PD-L1) expression.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.